Celsion Records Positive Data From Phase 2 DIGNITY Trial Of ThermoDox

(RTTNews) - Celsion Corp. (CLSN) Monday announced a positive interim data from its ongoing Phase 2 DIGNITY Trial of ThermoDox in patients with recurrent chest wall breast cancer. The reported five complete responses, four partial responses and four stable disease, while local response rate in 13 patients were 69 percent.

The company plans to enroll 20 patients for the ThermoDox study in combination with mild hyperthemia. It also plans to conduct Euro-DIGNITY trial in five countries to assess early stage breast cancer patients in a combination therapy using ThermoDox, hyperthermia and radiation.